Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
- 1 January 2006
- book chapter
- Published by Elsevier
- Vol. 96, 213-268
- https://doi.org/10.1016/s0065-230x(06)96008-4
Abstract
No abstract availableKeywords
This publication has 193 references indexed in Scilit:
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Initial sequencing and analysis of the human genomeNature, 2001
- A gene expression database for the molecular pharmacology of cancerNature Genetics, 2000
- The Hallmarks of CancerCell, 2000